Moderna mRNA Structure

FDA refuses review of mRNA flu vaccine

FDA won’t consider a new mRNA vaccine for flu despite the technology’s life-saving promise

The U.S. Food and Drug Administration is refusing to consider a new mRNA flu vaccine made by Moderna, the company revealed in a statement on Tuesday.

· 2d · on MSN

FDA declines to review Moderna's mRNA flu shot

· 1d

FDA Declines to Review Moderna’s mRNA Flu Vaccine Application

· 1d

FDA defends its decision to refuse review of Moderna's flu vaccine

Shares of Moderna (MRNA.O) slumped nearly 9% in premarket trading on Wednesday after the U.S. Food and Drug Administration declined to review the company's application for approval of its experimental...

· 13h

Moderna beats quarterly revenue estimates on resilient sales of COVID shot

· 1d

FDA refuses Moderna's application for new mRNA flu vaccine

Kalkine Media

Moderna (NASDAQ:MRNA) Aligned With Nasdaq Index Biotech Presence

Moderna advances messenger RNA platform technologies Therapeutics pipeline spans vaccines and disease targets nasdaq index inclusion reflects biotech scale Moderna, Inc. (NASDAQ:MRNA) operates within the biotechnology sector and remains a recognized component of the broader nasdaq index,

24/7 Wall St.

Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return. In fact, Moderna has the 12th-best gains in the entire S&P 500 so far in 2026!